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in themarket. Given the discrepancies between the decisions of the regulators and
the payers, drug manufacturers are obliged to demonstrate a product’s value to
patients and payers, as well as to show that it is safe and efficacious to regulators.
The incorporation of the payers’ viewpoint in the development process will ease
the gap between stakeholders.
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INCENTIVE-BASED INTERVENTIONS – REWARDING PATIENTS FOR GOOD
BEHAVIOUR
Haynes S, Costello S, Brooks-Rooney C, Hamer N
Costello Medical Consulting Ltd, Cambridge, UK
OBJECTIVES: Incentive-based schemes, in which patients are rewarded formaking
behaviour changes or reaching treatment goals, are becoming more common in
healthcare worldwide. Issues surrounding the cost effectiveness of behaviour
change, as well as the ethical implications of rewarding members of society who
exhibit inappropriate behaviours, are some of the issues which must be taken into
account when considering these schemes in real-life. The aim of this study was to
provide an account of incentive-based schemes currently under investigation, in
an effort to determine where the perceived benefits of these schemes may lie for
future implementation. METHODS: A Clinicaltrials.gov search was performed to
identify trials that specifically tested the use of incentives in encouraging behav-
iour modification in target populations. RESULTS: A total of 76 clinical trials, pre-
dominantly based in North America, were identified as appropriate for analysis.
The most commonly targeted groups included drug dependant individuals, over-
weight individuals (with exercise orweight-loss programmes) and smokers, imply-
ing that these schemes are most commonly used to induce lifestyle changes that
promote health. Most trials looked at the clinical-effectiveness of incentives at
achieving behaviour change, with minimal emphasis on the cost-effectiveness of
adding the incentive. The majority of the trials (43/76, 57%) used monetary or
voucher reimbursement systems as the incentive for patient behaviour modifica-
tion, with 10 additional schemes providing the opportunity to win a prize. Only 1
scheme directly linked reimbursement to treatment costs by providing a cycle of
treatment for free if the patient sustained compliance for a specified period.
CONCLUSIONS: The scope for the use of incentive-based schemes is broad, with
potential applications in numerous different diseases in which good compliance is
required; not just those which require lifestyle change. However, further economic
analysis of the cost-effectiveness of such schemes is essential before they are
implemented more widely.
Health Care Use & Policy Studies – Diagnosis Related Group
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EXPLORE THE USE OF DRUGS IN MEDICAL INSURANCE BILLING IN CHINA
Tan Z
Ministry of Labor and Social Security, Beijing, China
OBJECTIVES: With the advancement of the China health care reform and the in-
creasing health care expenditure, it is imperative to explore other billing methods
in addition to the existing item-based billing. Since 1980s, US and many other
countries have adopted DRGs to manage heath care insurance to control health
care expenditure and achieved positive outcomes. The objectives of this study are
to understand experiences from other countries in the implementation of DRGs
and make recommendations on how to adopt DRGs in China. METHODS: This
study started in 2003. It is composed of three phases: phase one is to study how
DRGs are implemented in the US, Australia, and Germany; phase two, the core part
of this study, is to analyze the grouping method. Based on learnings from US,
Australia, and Germany, we randomly collected 700000 patient records taking
place between 2002 and 2005 from 12 tier-one Beijing hospitals, developed a theo-
retical DRGs grouping model, and completed over 600 DRGs automated grouping
programs tailored for China; phase three contains analyses on the basic require-
ment of relevant policy and technology support to implement DRGs. RESULTS:
DRGs has been demonstrated to be an effective approach to manage health care
insurance in many countries. Considering China’s special situations (population,
health insurance system and policy environment), we developed and piloted DRGs
in 12 tier-one hospitals in Beijing in 2010. We will further evaluate the impact of
this program in the future. CONCLUSIONS: The successful implementation of
DRGs depends on an appropriate policy environment and mature technology sup-
port. Currently China is not ready to launch DRGs nationally yet due to the lack of
policy environment and technology support.
Health Care Use & Policy Studies – Drug/Device/Diagnostic Use & Policy
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DEVELOPING PUBLIC HEALTH GUIDANCE - WHAT ARE THE DATA GAPS?
REVIEW OF THE GAPS IN THE EVIDENCE IDENTIFIED BY NICE IN THE UNITED
KINGDOM
Kusel J, Costello S, Hamer N, Roper S, Hamerslag L
Costello Medical Consulting Ltd, Cambridge, UK
OBJECTIVES: Public health policy is understood to be a major determinant of over-
all population health. However, developing public health guidance can be difficult
due to the lack of sufficient evidence on the effectiveness and cost-effectiveness of
possible interventions. The objective of this studywas to identify themajor gaps in
the evidence base that has been used to develop public health guidance.
METHODS: The gaps identified by the UK National Institute for Health and Clinical
Excellence (NICE) in the evidence that was used for the development of their 31
public health guidance documents published as of December 2010 were assessed
and compared. RESULTS: The most prevalent data gap, identified by 25 of the 31
guidance documents, was a lack of evidence on the effectiveness of public health
interventions in specific subgroups of the population, particularly ethnic minori-
ties, age subgroups and those from disadvantaged backgrounds. The secondmajor
gap in the evidence, discussed by 21 documents, was a lack of data specific to the
country of interest (in this case, the UK). Nineteen documents reported the lack of
cost-effectiveness evidence as a barrier to developing public health guidance and 4
of these specifically noted the difficulty of generating QALYs in the public health
arena. Further major data gaps included a lack of well-designed studies (14 docu-
ments), a lack of long-term outcomes (13), insufficient evaluation of which ele-
ments of an interventionmake it effective (9) and a lack of evidence on the relative
effectiveness of interventions (8). CONCLUSIONS: Research into public health in-
terventions and issues is of paramount importance. Researchers should focus ef-
forts upon identifying particular subgroups in which interventions are particularly
effective or ineffective and on generating country-specific data. Cost-effectiveness
data is particularly lacking; one solution would be to devise newmethods of QALY
measurement in public health situations.
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OBJECTIVES: This study investigates the extent to which geographic variation in
adequacy of primary care and specialist supply explains variation in patient use of
prescribed medications to treat chronic conditions. METHODS: Generalized Least
Squares regression with period random effects was used on a pooled data set of
monthly (May 2006 to Oct 2010) IMS Health data for 360 Metropolitan Statistical
Areas (MSAs). The dependent variablewas totalmonthly prescriptions perMSA for:
(1) Statins, (2) PPIs, (3) Anti-psych, and (4) asthma/COPD. Separate regressionswere
estimated by therapeutic category and by payer type. Explanatory variables include
monthly: (1) size of the population with the chronic condition;(2) economic envi-
ronment; (3) dummy event variables; and (4) level of Rx advertising. Estimates of
the shortfall of primary care providers and specialists in each State in 2010 are
included as explanatory variables. For state-level shortfall, provider demand esti-
mates were based on national healthcare use and delivery patterns applied to each
State’s population controlling for demographics, rates of uninsured, and obesity
rates. RESULTS: There exists a direct correlation between estimated adequacy of
primary care and specialist (cardiologist, gastroenterologist, psychiatrist, pul-
monologist, and allergist) supply and volume of prescriptions. The patterns are
relatively consistent across therapeutic areas. For the Statinmarket, each 1% short-
fall of cardiologists is associated with 0.36%, 0.43%, and 0.79% decrease in Statin Rx
volume for the commercially insured,Medicare, andMedicaid populations, respec-
tively. Each 1% shortfall of primary care providers is associated with decreases in
volume across in the commercially insured (0.15%) and Medicaid (0.83%)
populations. CONCLUSIONS: This research suggests that controlling for economic
and population risk factors, greater inadequacy of physician supply is associated
with lower use of prescriptions for treating chronic conditions. Physician shortages
disproportionally affect access to medications for the Medicaid population, fol-
lowed by the Medicare and commercially insured populations.
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IMPACT OF FREE PRESCRIPTIONS IN WALES ON PRESCRIBING - A THIN
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OBJECTIVES: The Welsh Assembly Government introduced free prescriptions for
all on 1st April 2007. In the other UK countries, prescriptions were around £6 each,
although children, elderly and other exemptions applied. This study evaluated
whether the Welsh policy change impacted levels of prescribing.METHODS: Total
numbers of prescription itemswere calculated for eight 12-month periods between
1st July 2001 and 30th June 2009 from The Health Improvement Network (THIN),
which contains anonymised longitudinal UK primary care data. The number of
prescriptions was divided by number of actively registered patients for each time
period, country and age category (0-21, 22-59 and 60 years old). Percentage
changes between periods were calculated and all results described. RESULTS: In
Wales therewere 19.5 prescriptions/patient in the 2001/2002 period, which steadily
increased to 26.9 in the 2008/2009 period. In England, prescriptions/patient in-
creased from 15.1 to 21.3, Scotland 15.4 to 20.2, Northern Ireland (NI) 16.7 to 21.9.
The percentage change between 2006/2007 and 2007/2008 was 4.2% in Wales, 4.9%
England, 3.1% Scotland, 4.3% NI. The change within the 0-21 year olds was 4.0%,
1.7%, 2.6% and 0.8% respectively. For 22-59 year olds it was 6.6%, 3.0%, 2.5% and
3.7% respectively. For 60 year olds it was 2.8%, 5.1%, 2.9% and 4.3% respectively.
CONCLUSIONS: The descriptive results suggest that overall the policy change did
not seem to impact levels of prescribing in Wales as the percentage change was
similar across countries. However, the percentage change for the 0-21 and 22-59
age groups was higher in Wales, whereas the percentage change for the 60 age
group, who were already exempt from prescription charges, was lower. This could
suggest that prescribing increased for patients who were previously most affected
by prescription charges. Future studies could evaluatewhether prescribing of certain
drug classes, especially those including over-the-counter products, was affected.
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OBJECTIVES:Deaths due to opioid over-dosage have increased over the last decade
and now represent the most frequent cause of death due to poisoning. This study
examined the temporal association between prescription opioid use between 2000
and 2005 and the number of opioid-poisoning deaths. METHODS: The number of
annual opioid-poisoning deaths from 2000-05was obtained from theNational Vital
Statistics System multiple causes of injury mortality files (Warner 2009). Data for
annual prescription opioid use was obtained from a published study that reported
opioid use from 2.7 to 3.8 million enrollees annually using the HealthCore Blue
Cross and Blue Shield national commercial insurance plans (Sullivan 2008). The
temporal relationship between several opioid use measures and the number of
opioid deaths/year was studied using ordinary least square regression. RESULTS:
The cumulative opioid dose among all recipients increased from204mgsmorphine
equivalents/enrollee/year to 371 mgs and among opioid users with a non-cancer
pain diagnosis from 2473mgs to 3406mgs. During this period, the number of yearly
opioid deaths increased from4,419 in 2000 to 10,947 in 2005. Therewas a significant
linear relationship between the cumulative yearly opioid dose/enrollee/year and
the number of opioid-poisoning deaths (p0.0001, R20.98). A significant positive
linear relationshipwas also observed between thenumber of annual opioid-related
deaths and opioid use measures of cumulative yearly opioid dose (p0.0001,
R20.98), opioid dose/prescription (p0.0053, R20.88) and mean days-supplied of
opioids/year (p0.0001, R20.99). CONCLUSIONS: A strong linear relationship be-
tween opioid-poisoning deaths and several prescription opioid use measures sug-
gests that the acquisition of prescribed opioids through legal channels is associated
with the national opioidmortality rate. This calls for added vigilance on the part of
prescribers and policy makers to ensure safe use of opioid analgesics. Further
research is warranted to confirm these correlations.
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OBJECTIVES: Essential Medicine policy is a important component of China’s un-
dergoing healthcare reform,while the essential medicine list(the “EML”) is the core
of the essential medicine policy. On August 18, 2009, China issued national essen-
tial medicine list (the “NEML”,1st edition) with 205 western medicines and 102
traditional Chinese medicines(the “TCM”) in it, and each province can add further
medicines to the NEML to form its own provincial essential medicine list (the
“PEML”) under specific circumstances. This paper aims at supporting for the next
round adjustment of the NEML through analyzing the situation of addition to the
NEML by each province. METHODS: To study the addition to the NEML by each
province, this paper analyzes the number of medicines added to NEML in all 31
provincial regions in china during the period of August 18, 2009 to January 1, 2011
through searching the official websites, spot investigation and interview the
officials. RESULTS: (1) So far there are 18 provincial regions having added further
medicines to the EML; (2) Regardless of folk medicine, the average number of es-
sential medicines added in each province is 187,among which western medicines
added 115 while the TCM added 72. (3) Shanghai added the largest number of
medicines to its PEML, i.e. 381,while Qinghai Province added the smallest number
of 60. (4)Some autonomous regions added folk medicines to the PEML according to
the local conditions. CONCLUSIONS: (1) it’s necessary for China to adjust the
NEML(1st edition) reasonably based on the number ofmedicines added to the PEML
and drug using characteristics in each province;(2)The more developed the econ-
omy, the more the further essential medicines added, which leads to unfair and
lower the accessiblity to essential medicines in poor areas, thus the government
should increase investment in poor areas.
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OBJECTIVES: To assess the influence of a quality improvement initiative on the
rate of potentially inappropriate medications (PIMs) in primary care elderly
patients.METHODS: A 3-year, multi-phase prospective demonstration project tar-
geting all 303 general practitioners (GPs) in the Local Health Authority (LHU) of
Parma, Italy, was established in 2007. A panel of Parma LHUexperts developed a list
of PIMs deemed to be always avoided for older patients according to the literature.
The quality improvement intervention delivered to GPs hinged upon increasing
physicians’ awareness of prescribing for the elderly and included three key ele-
ments: i) the initial dissemination of the developed PIMs list, along with a list of
alternative drugs to PIMs; ii) annual reviews of PIMs prevalence data; and (iii) a
series of educational sessions on PIMs via academic detailing and case studies
reviews.We used a pre-post design to analyze the change in quarterly rates of PIMs
in elderly patients aged 365 years in Parma LHU between the study start (pre-
intervention - 2007 fourth quarter (Q4)) and the end of the study (post-intervention
– 2009 Q4), using a neighboring LHU similar in size as a comparator. RESULTS: The
prescription rate of PIMs in the elderly of Parma LHU declined by 19%, from 6.3%
pre-intervention (2007 Q4) to 5.1% post-intervention (2009 Q4), compared to a 12%
reduction in the same time period in the comparator LHU, from 6.8% to 5.9%. The
degree of decline in the rate of PIMs was significantly greater in the LHU of Parma
(Breslow-Day test, p0.004). CONCLUSIONS: A quality intervention program look-
ing at improving knowledge in primary care physicians on prescribing for the el-
derly patients resulted in a substantial reduction of the rate of PIMs. Additional
approaches targeting specific medications or physician characteristics should be
developed to further reduce PIMs rates.
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THE EFFECTS OF PHARMACEUTICAL COST CONTAINMENT ON ACCESS TO
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OBJECTIVES: Pharmaceutical cost containment policies can affect access to med-
icines. The present study compares medicines licensed in the United States (US),
United Kingdom (UK), Australia and New Zealand (NZ), and subsidized by the US
Department of Veterans Affairs National Formulary (VANF), UK National Health
Service (NHS), Australian Pharmaceutical Benefits Scheme (PBS) and NZ’s PHARMAC.
We compare licensed and subsidized medicines in terms of: (i) total numbers of
entities (unique ATC codes), (ii) times since first registration (“age”) of entities, and
(iii) numbers of innovative entities. METHODS: All products listed in a major pre-
scribing reference text in each country were classified by ATC code and their reg-
istration dates recorded. Innovative entities given “fast track” approval by the US
Food and Drug Administration or “breakthrough or substantial improvement” sta-
tus by the Canadian Patented Medicines Review Board were identified. RESULTS:
Of the 918 entities and 64 innovative entities licensed in the US, 505 and 20 respec-
tively were VANF subsidized. In the UK, this was 1020 and 58 (1016 and 58 NHS
subsidized), Australia 879 and 49 (567 and 30 PBS subsidized) andNZ 765 and 39 (503
and 19 PHARMAC subsidized). With the exception of the UK, US licensed entities
were “newer” than elsewhere: US median “age” 6,607 days (VANF 8,203 days, p
0.001), UK 7,319 days (NHS 7,319 days, p 0.903), Australia 7,795 days (PBS 8,065
days, p 0.406), NZ 8,936 days (PHARMAC 10,724 days P0.001). NHS subsidized
entities were “newer” than elsewhere. In the US and NZ, subsidized entities were
significantly “older” than licensed entities. CONCLUSIONS: Different pharmaceu-
tical cost containment policies appear to impact the number and “age” of licensed
and subsidized entities, along with access to innovative entities. The New Zealand
system had the strongest cost containment levers, but subsidised the fewest and
“oldest” entities, and fewest innovative entities.
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OBJECTIVES: The objectives of the survey were to gather information on percep-
tions about biologic agents from payers and providers presently and over the next
18months. Areas of focus included: (1) Perceptions of healthcare reformon biologic
product development, access and reimbursement, and outcomes research require-
ments; (2) Biosimilar pricing; (3) Use of specialty pharmacy providers; (4) Improve-
ments in quality of care, outcomes and costs of target diseases. METHODS: An
online survey was conducted with a select sample of national stakeholders repre-
senting payers and providers during the 4th quarter 2010. RESULTS: Over 80 re-
spondents representing multiple types of payers and providers (ex: health plans,
fed and state government agencies, health systems,) participated in the survey.
Fifty percent (50%) of payers and 30% of providers did not know the percentage of
their organization’s health care spend on biologics, but nearly all knew that their
organization’s health care spend on biologics is increasingly important. Payers and
providers agree (7.7/10 and 7.6/10) that patients will incur more out of pocket ex-
penses for biologics over the next 6-18 months. The 3 greatest areas indicated by
providers and payers for improvement in quality of care and outcomes are: Oncol-
ogy-early stage, RA, and AD. It is perceived that generically interchangeable bio-
similars will be available at an approximate 40% discount. Respondents felt estab-
lishing a value proposition and promoting appropriate use will be key drivers of
importance for biologic agents in the future. Respondents agree that their needs
regarding biologic agents should focus on: outcomes measurement, comparative
effectiveness studies, specialty pharmacy usage, benefit designs, and regulatory
developments through educational initiatives. CONCLUSIONS: Biologics remain a
strong growing area of interest among healthcare stakeholders and monitoring
changes inmarketplace dynamicswith additional research effortswill be key areas
of focus in the future.
PHP16
ANALYZING THE EUROPEAN EXTERNAL REFERENCE PRICING SYSTEM USING
SPECTRAL GRAPH THEORY
Lindgren P1, Åkerborg Ö2
1i3 Innovus, San Diego, CA, USA, 2i3 Innovus, Stockholm, Sweden
OBJECTIVES: Many countries employ an external reference pricing system where
the price of pharmaceutical is in part governed by the price in selected other coun-
tries thus creating a web of relationships between the prices in different countries.
The objective of this study was to investigate which countries could be considered
the most influential in this network. METHODS: The price referencing pattern
between countries in the European Economic Area was represented as a directed
graphwith each individual country as a node and the existence of price referencing
from one country to another as a directed edge. The importance of each country
was estimated by calculating the eigenvector centrality of each node based on the
adjacency matrix representing the edges of the graph. In an extension, we also
performed an analysis where edges were weighted by the size of the pharmaceu-
tical market in each country. RESULTS:When considering unweighted referencing
between countries, Germany and France were the two most influential countries
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